China’s NDRC to survey production costs of pharmaceutical companies
China’s National Development and Reform Commission has launched a detailed survey of production costs at 60 domestic and international pharmaceutical companies. Targeted companies include the China operations of GlaxoSmithKline, Merck, Sandoz...To view the full article, register now.
Already a subscriber? Click here to view full article